Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free PTGX Stock Alerts

Protagonist Therapeutics (PTGX) Stock Chart & Stock Price History

Protagonist Therapeutics logo
$104.96 +1.08 (+1.03%)
As of 02:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Protagonist Therapeutics Stock Price Performance

The Protagonist Therapeutics (PTGX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 139.79%, with a year-to-date return of 20.17%. In the past month, the stock has increased 0.22%, reflecting recent market activity.

As of the latest close, Protagonist Therapeutics traded at $103.88 with a market cap of $6.68 billion and volume of 518,199 shares. Five years ago, the stock traded at $30.47, representing a 244.45% increase over that period. At the time, it had a market cap of $1.34 billion and a volume of 239,212 shares.

Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
5 Day
Performance
+5.63%
1 Month
Performance
+0.22%
3 Month
Performance
+28.79%
Year-To-Date
Performance
+20.17%
1 Year
Performance
+139.79%
5 Year
Performance
+244.45%

PTGX Stock Chart for Thursday, May, 14, 2026

PTGX Chart by TradingView

Protagonist Therapeutics Stock Price History

Export
DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization
05/13/2026$99.95$103.88
+3.93%		$104.20$98.22518,199 shs$6.68 billion
05/12/2026$103.50$99.95
-3.43%		$103.66$98.36645,707 shs$6.43 billion
05/11/2026$99.36$103.50
+4.17%		$105.33$99.94572,030 shs$6.66 billion
05/08/2026$98.85$99.36
+0.52%		$100.15$97.00504,964 shs$6.36 billion
05/07/2026$103.97$98.85
-4.92%		$104.68$98.53836,856 shs$6.36 billion
05/06/2026$99.21$103.97
+4.80%		$105.03$98.95989,856 shs$6.69 billion
05/05/2026N/A$99.21$101.37$97.45392,055 shs$6.38 billion
04/30/2026$98.52$98.97
+0.46%		$99.76$97.20577,600 shs$6.32 billion
04/29/2026$101.21$98.52
-2.66%		$100.35$98.11576,688 shs$6.29 billion
04/28/2026$98.81$101.21
+2.43%		$102.47$97.79663,208 shs$6.46 billion
04/27/2026$100.00$98.81
-1.19%		$103.42$98.31994,860 shs$6.30 billion
04/24/2026$102.62$100.00
-2.55%		$105.94$98.91778,707 shs$6.38 billion
04/23/2026$105.55$102.62
-2.78%		$106.98$102.26651,593 shs$6.55 billion
04/22/2026$105.89$105.55
-0.32%		$107.00$103.93345,925 shs$6.74 billion
04/21/2026$105.47$105.89
+0.40%		$106.45$103.64494,943 shs$6.76 billion
04/20/2026$105.98$105.47
-0.48%		$106.46$104.00540,469 shs$6.73 billion
04/17/2026$103.73$105.98
+2.17%		$106.90$103.511.01 million shs$6.76 billion
04/16/2026$105.44$103.73
-1.62%		$104.53$102.46417,822 shs$6.62 billion
04/15/2026$104.72$105.44
+0.69%		$106.66$103.02770,162 shs$6.73 billion
04/14/2026$97.57$104.72
+7.33%		$104.97$97.58849,462 shs$6.68 billion
04/13/2026$98.82$97.57
-1.26%		$101.04$95.401.09 million shs$6.23 billion
Related Companies

This page (NASDAQ:PTGX) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners
NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measl...
Equiscreen | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
Millionaire warns: Move your money before May 15
Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...
Brownstone Research | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel